Bionor is a biopharmaceutical company with first mover potential to advance a possible functional HIV cure

Latest news

Hide mandatory notifications of trade

Bionor granted up to NOK 10.3 million from Research Council of Norway to further advance Vacc-4x in a combination treatment regimen

Financial .2017

(Oslo, Norway, 27 January 2017) Bionor Pharma AS, a wholly owned subsidiary of Solon Eiendom ASA (OSE:SOLON) announces today that the Research Council of Norway (RCN) through its BIA Program (Brukerstyrt Innovasjonsarena), has awarded the company up to NOK 10.3 million to partially fund an exploratory Phase I/II trial of Vacc-4x in combination with an immune regulating agent and a neutralizing antibody.

Solon Eiendom ASA – Publication of prospectus, listing of new shares and start of subscription period

Financial .2017

(Oslo, Norway, 13 January 2017) Reference is made to a stock exchange announcement by Solon Eiendom ASA ("Solon" or the "Company", ticker "SOLON") on 12 January 2017 regarding approval of the Company's prospectus dated 12 January 2017 (the "Prospectus"), listing of new shares and further information on a subsequent offering of shares in the Company.

Bionor granted up to NOK 10.3 million from Research Council of Norway to further advance Vacc-4x in a combination treatment regimen

Financial .2017

(Oslo, Norway, 27 January 2017) Bionor Pharma AS, a wholly owned subsidiary of Solon Eiendom ASA (OSE:SOLON) announces today that the Research Council of Norway (RCN) through its BIA Program (Brukerstyrt Innovasjonsarena), has awarded the company up to NOK 10.3 million to partially fund an exploratory Phase I/II trial of Vacc-4x in combination with an immune regulating agent and a neutralizing antibody.

Solon Eiendom ASA – Publication of prospectus, listing of new shares and start of subscription period

Financial .2017

(Oslo, Norway, 13 January 2017) Reference is made to a stock exchange announcement by Solon Eiendom ASA ("Solon" or the "Company", ticker "SOLON") on 12 January 2017 regarding approval of the Company's prospectus dated 12 January 2017 (the "Prospectus"), listing of new shares and further information on a subsequent offering of shares in the Company.

Go to news section

Featured content